Allergan builds case for migraine drug ubrogepant as FDA verdict nears

Allergan builds case for migraine drug ubrogepant as FDA verdict nears

Source: 
Pharmaforum
snippet: 

Allergan’s ubrogepant could become the first oral drug in the new CGRP inhibitor class if it is approved by the FDA in December, but is still facing a challenge in the market.